Overview

This trial is active, not recruiting.

Condition non-small-cell lung cancer
Sponsor Istituto Clinico Humanitas
Start date September 2008
End date September 2008
Trial size 100 participants
Trial identifier NCT00831454, ONC/OSS-02/2008

Summary

The aim of this study was to retrospectively evaluate associations between EGFR and AKT DNA-polymorphisms involved in transcriptional regulation and overall survival in NSCLC patients treated with EGFR-TKIs.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective retrospective

Primary Outcomes

Measure
to evaluate the presence of EGFR- and AKT-DNA polymorphisms.
time frame: At the end of enrollment

Secondary Outcomes

Measure
to correlate the biological characteristics with clinical characteristics and survival data of patients.
time frame: At the end of enrollment

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Availability of tumor tissue or blood samples.

Additional Information

Official title RELATIONSHIP OF POLYMORPHISMS AND MUTATIONS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND TYROSINE KINASE INHIBITORS RESPONSIVENESS IN NON-SMALL-CELL LUNG CANCER PATIENT
Principal investigator Armando Santoro, MD
Description DNA will be isolated from blood samples or paraffin-embedded tumor specimens and than a mutation analysis and SNPs genotyping will be done.
Trial information was received from ClinicalTrials.gov and was last updated in September 2010.
Information provided to ClinicalTrials.gov by Istituto Clinico Humanitas.